Study of a new cell therapy for recurrent high-grade brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial is testing a new type of cell therapy called CAR-T that targets a marker (B7-H3) on brain tumor cells. It is for people with grade 4 gliomas that have returned after standard treatment, and it aims to see if this treatment can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have a grade 4 brain tumor (like glioblastoma) that has come back or worsened after standard treatment.
- Your tumor must have at least 30% of a certain marker called B7-H3, which will be checked with a lab test.
- You must be in fairly good health, with a performance score of 60 or higher (KPS) or 0-1 on the ECOG scale.
- You must have adequate organ function, including blood counts, liver, kidney, and heart function.
- You cannot have had prior CAR-T therapy or other gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Hear when a new R/R Grade 4 Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.